CL2021001177A1 - Compuestos químicos - Google Patents

Compuestos químicos

Info

Publication number
CL2021001177A1
CL2021001177A1 CL2021001177A CL2021001177A CL2021001177A1 CL 2021001177 A1 CL2021001177 A1 CL 2021001177A1 CL 2021001177 A CL2021001177 A CL 2021001177A CL 2021001177 A CL2021001177 A CL 2021001177A CL 2021001177 A1 CL2021001177 A1 CL 2021001177A1
Authority
CL
Chile
Prior art keywords
compounds
atopic dermatitis
chemical compounds
inhibitors
pruritus
Prior art date
Application number
CL2021001177A
Other languages
English (en)
Inventor
Jason D Speake
Bharathi Pandi
Joe B Perales
Weiming Fan
Original Assignee
Avista Pharma Solutions Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Avista Pharma Solutions Inc filed Critical Avista Pharma Solutions Inc
Publication of CL2021001177A1 publication Critical patent/CL2021001177A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invención describe nuevos compuestos, o sales farmacéuticamente aceptables de los mismos, composiciones farmacéuticas que los contienen y sus usos médicos. Los compuestos de la invención tienen actividad como inhibidores de Janus Kinase y son útiles en el tratamiento o control del prurito asociado con dermatitis alérgica, dermatitis atópica en animales y otros trastornos e indicaciones en las que sería deseable la inmunosupresión/inmunomodulación. También se describen en este documento métodos para tratar el prurito y la dermatitis atópica mediante la administración de los compuestos de la invención, los cuales son inhibidores de JAK 1.
CL2021001177A 2018-11-05 2021-05-05 Compuestos químicos CL2021001177A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862755679P 2018-11-05 2018-11-05

Publications (1)

Publication Number Publication Date
CL2021001177A1 true CL2021001177A1 (es) 2022-05-27

Family

ID=70458378

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2021001177A CL2021001177A1 (es) 2018-11-05 2021-05-05 Compuestos químicos

Country Status (11)

Country Link
US (1) US10744136B2 (es)
EP (1) EP3877389A4 (es)
JP (1) JP2022506682A (es)
KR (1) KR20210072125A (es)
CN (1) CN113272306A (es)
AU (1) AU2019375412A1 (es)
BR (1) BR112021008742A2 (es)
CA (1) CA3118488A1 (es)
CL (1) CL2021001177A1 (es)
MX (1) MX2021005334A (es)
WO (1) WO2020096948A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090053786A1 (en) 2007-07-09 2009-02-26 Yung-Hsiang Kao Prevention of disulfide bond reduction during recombinant production of polypeptides

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100415791B1 (ko) * 1998-06-19 2004-01-24 화이자 프로덕츠 인코포레이티드 피롤로[2,3-디]피리미딘 화합물
BRPI0809992A2 (pt) * 2007-04-02 2014-10-14 Palau Pharma Sa Derivados de pirrolopirimidina
RU2493157C2 (ru) * 2008-08-20 2013-09-20 Пфайзер Инк. ПРОИЗВОДНЫЕ ПИРРОЛО[2,3-d]ПИРИМИДИНА
DK2958921T3 (da) * 2013-02-22 2017-11-06 Pfizer Pyrrolo[2,3-D]pyrimidin-derivater som hæmmere af Janus kinaser (JAK)
KR102275326B1 (ko) * 2013-06-07 2021-07-12 지앙수 헨그루이 메디슨 컴퍼니 리미티드 야누스 키나제(jak) 억제제의 바이설페이트 및 그의 제조 방법
EP3180344B1 (en) * 2014-08-12 2019-09-18 Pfizer Inc Pyrrolo[2,3-d]pyrimidine derivatives useful for inhibiting janus kinase
JP7462951B2 (ja) * 2018-03-21 2024-04-08 リャオ，シビン Ｊａｋ阻害剤

Also Published As

Publication number Publication date
JP2022506682A (ja) 2022-01-17
MX2021005334A (es) 2021-06-23
WO2020096948A1 (en) 2020-05-14
US10744136B2 (en) 2020-08-18
AU2019375412A1 (en) 2021-06-03
BR112021008742A2 (pt) 2021-08-10
KR20210072125A (ko) 2021-06-16
EP3877389A1 (en) 2021-09-15
CN113272306A (zh) 2021-08-17
CA3118488A1 (en) 2020-05-14
US20200138811A1 (en) 2020-05-07
EP3877389A4 (en) 2022-07-13

Similar Documents

Publication Publication Date Title
CL2018002516A1 (es) Inhibidores de mcl-1 indólicos sustituidos.
CU20190073A7 (es) 2-heteroaril-3-oxo-2,3-dihidropiridazin-4-carboxamidas
EA201791874A1 (ru) Фторированные ингибиторы лизилоксидазоподобного фермента-2 и их применение
BR112017007975A2 (pt) composições e métodos para o tratamento de disfunção das glândulas meibomianas
UY36371A (es) Compuestos de indolcarboxamida inhibidores de quinasas tipo btk y tipo tec
BR112017011923A2 (pt) bactéria modificada para tratar doenças associadas com hiperamonemia
NI201700029A (es) Compuestos y composiciones como inhibidores de quinasa raf.
EA201892431A1 (ru) Олигонуклеотиды для лечения заболевания глаз
ECSP18073293A (es) Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue
CO2018005315A2 (es) Moduladores de la interacción de sestrina-gator2 y sus usos
ECSP13013068A (es) Halogenoalquil-1,3-oxazinas como inhibidores de la bace1 y/o bace2
BR112017007063A2 (pt) ?composições e métodos para o tratamento de insônia?
GT201400222A (es) Agentes para tratar trastornos que implican la modulación de receptores de rianodina
CO2018013803A2 (es) 1h-pirazolo[4,3-b]piridinas como inhibidores de pde1
CL2019001658A1 (es) Derivados de la pirimidin enona tricíclica para la inhibición de rory y otros usos.
CL2019000661A1 (es) Inhibidores de dopamina–b–hidroxilasa penetrantes de la barrera hematoencefálica.
NI201600176A (es) Compuestos de 1, 3, 4 - tiadiazol y uso de los mismos para el tratamiento del cáncer.
DOP2020000072A (es) Amidas de imidazopiridina sustituidas y su uso
DOP2016000170A (es) Compuestos derivados de hidroxiformamida y usos del mismo
UY37729A (es) NUEVOS COMPUESTOS QUE INHIBEN LA ACTIVIDAD DE Nav1.7
CO2022007814A2 (es) Ligandos de la pseudoquinasa tyk2
CL2021001656A1 (es) Compuestos de imidazopiridina e imidazopiridina y sus usos.
CL2020001550A1 (es) Tratamientos combinados que comprenden la administración de 1h-pirazolo[4,3-b]piridinas.
PH12020551179A1 (en) Methods for treating mitochondrial disorder
CL2022003703A1 (es) Compuestos antibióticos, métodos de fabricación de los mismos, composiciones farmacéuticas conteniendo los mismos y usos